Jasper Therapeutics Inc
JSPR
Company Profile
Business description
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Contact
2200 Bridge Parkway
Suite 102
RedwoodCA94065
USAT: +1 650 549-1400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
The best AI stocks to buy now
Artificial intelligence stocks maintain their allure, thanks to industry momentum and appealing valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,871.30 | 48.10 | 0.55% |
| CAC 40 | 7,729.69 | 39.52 | -0.51% |
| DAX 40 | 24,806.97 | 297.39 | -1.18% |
| Dow JONES (US) | 51,231.64 | 51.77 | 0.10% |
| FTSE 100 | 10,441.60 | 16.90 | -0.16% |
| HKSE | 24,079.30 | 293.51 | 1.23% |
| NASDAQ | 27,193.34 | 345.35 | -1.25% |
| Nikkei 225 | 68,512.30 | 529.81 | -0.77% |
| NZX 50 Index | 13,720.44 | 28.59 | 0.21% |
| S&P 500 | 7,765.36 | 36.41 | -0.47% |
| S&P/ASX 200 | 8,708.70 | 47.80 | 0.55% |
| SSE Composite Index | 3,764.35 | 47.55 | -1.25% |